Cargando…
Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet
INTRODUCTION: Tyrosinemia Type 1 (HT1) is an autosomal recessive disorder caused by a defect in the enzyme fumarylacetoacetate hydroxylase in the tyrosine pathway. Implementation of nitisinone (NTBC) treatment has dramatically improved survival rate of individuals with HT1, yet recent reports on cog...
Autores principales: | García, María Ignacia, de la Parra, Alicia, Arias, Carolina, Arredondo, Miguel, Cabello, Juan Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369864/ https://www.ncbi.nlm.nih.gov/pubmed/28377889 http://dx.doi.org/10.1016/j.ymgmr.2017.01.016 |
Ejemplares similares
-
Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria
por: Hughes, Juliette H., et al.
Publicado: (2020) -
Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain
por: Couce, María Luz, et al.
Publicado: (2019) -
Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia
por: HONAR, Naser, et al.
Publicado: (2017) -
Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
por: Das, Anibh Martin
Publicado: (2017) -
Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion
por: Jack, Rhona M., et al.
Publicado: (2019)